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Although neutralizing monoclonal antibodies (mAbs) against epitopes within the alphavirus E2 protein can
protect against infection, the functional significance of non-neutralizing mAbs is poorly understood. Here,
we evaluate the activity of 13 non-neutralizing mAbs against Mayaro virus (MAYV), an emerging arthritogenic
alphavirus. These mAbs bind to the MAYV virion and surface of infected cells but fail to neutralize infection in
cell culture. Mapping studies identify sixmAb binding groups that localize to discrete epitopes within or adja-
cent to the A domain of the E2 glycoprotein. Remarkably, passive transfer of non-neutralizing mAbs protects
against MAYV infection and disease in mice, and their efficacy requires Fc effector functions. Monocytes
mediate the protection of non-neutralizing mAbs in vivo, as Fcg-receptor-expressing myeloid cells facilitate
the binding, uptake, and clearance of MAYVwithout antibody-dependent enhancement of infection. Humoral
protection against alphaviruses likely reflects contributions from non-neutralizing antibodies through Fc-
dependent mechanisms that accelerate viral clearance.
INTRODUCTION
Alphaviruses are mosquito-transmitted, positive-sense RNA
viruses in the Togaviridae family and are classified into groups
based on genetic relatedness and disease potential. Enceph-
alitic alphaviruses, including Eastern, Western, and Venezue-
lan equine encephalitic viruses (EEEV, WEEV, and VEEV,
respectively), infect neuronal cells, which can lead to enceph-
alitis and death. Arthritogenic alphaviruses, including chikun-
gunya (CHIKV), Ross River (RRV), O’nyong-nyong (ONNV),
and Mayaro (MAYV) viruses, infect joint-associated tissues
and cause acute and chronic musculoskeletal disease.
MAYV was described in 1954 in Trinidad (Causey and Maroja,
1957) and circulates in the Caribbean Islands and South Amer-
ica (Azevedo et al., 2009; Causey and Maroja, 1957; Pinheiro
et al., 1981). MAYV infection causes an acute febrile illness
that can progress to acute and chronic arthritis, much like
CHIKV (Halsey et al., 2013). Due to serum cross-reactivity
and overlapping epidemiology with CHIKV, MAYV infections
may be more prevalent than previously appreciated (Hozé
et al., 2020). Currently, no treatments are approved for any al-
phavirus infection.
The alphavirus virion is comprised of a single 11.4-kb RNA
genome encapsidated in a nucleocapsid core and surrounded
by a host-derived membrane. The genome encodes for four
non-structural proteins, namely, nsP1–4, which mediate viral
translation, viral replication, and host subversion and evasion
(Rupp et al., 2015); and six structural proteins, namely, capsid,
E3, E2, 6K, transframe (TF), and E1. The viral glycoproteins are
cleaved from a structural polyprotein precursor and form the
heterodimer p62(E3-E2)-E1. p62 is cleaved by furin proteases
in the trans-Golgi network (Heidner et al., 1996), and the mature
E2 and E1 proteins transit to the surface of the cell where they
may still associate with E3 (Uchime et al., 2013; Yap et al.,
2017). Virion morphogenesis occurs at the plasma membrane,
and the mature virion displays trimers of E2-E1 heterodimers
assembled into higher order spikes. The virus is released into
the extracellular space by budding (Carleton et al., 1997).
Because E1 and E2 proteins are exposed on virions and the
surface of infected cells, they are the targets of the host anti-
body response.
Antibody-mediated protection from alphavirus infection
occurs through several mechanisms, including neutralization
by inhibiting virus attachment, entry, fusion, and/or egress
from host cells (Earnest et al., 2019; Fox et al., 2015; Jin and Sim-
mons, 2019). Indeed, neutralizing monoclonal antibodies (mAbs)
that bind the B domain of MAYV E2 prevent virus-cell membrane
fusion or viral egress (Earnest et al., 2019). The efficacy of
Cell Reports 35, 108962, April 6, 2021 ª 2021 The Author(s). 1
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
ll
OPEN ACCESS
anti-alphavirus neutralizing antibodies in vivo also is modulated
by Fc effector functions (Earnest et al., 2019; Fox et al., 2019).
Antibodies that bind to viral proteins on the surface of infected
cells may facilitate complement deposition and/or innate im-
mune cell targeting (Bournazos et al., 2015; Lu et al., 2018).
Little is known about the functional significance of non-
neutralizing antibodies in the context of infection and immunity
of alphaviruses or other families of enveloped viruses. Here,
we isolated a panel of murine mAbs against theMAYV E2 protein
of the IgG2c subclass with no measurable neutralizing activity
in vitro. These mAbs bound virions in a capture ELISA and map-
ped to six distinct epitopes within or proximal to the A domain of
the E2 of MAYV. Remarkably, the majority of non-neutralizing
mAbs conferred protection against arthritis in immunocompe-
tent mice and prevented lethal challenge in immunodeficient
mice. Protection in vivo was immunoglobulin G (IgG) subclass
and Fcg receptor (FcgR) dependent and required the presence
of monocytes. Mechanism of action studies showed that non-
neutralizing mAbs can enhance the binding, uptake, and clear-
ance of MAYV on FcgR-expressing myeloid cells. Our results
indicate that direct neutralization is not required for antibody-
mediated protection, as Fc effector functions and monocytes
can promote antibody-dependent control of alphavirus infection.
RESULTS
Isolation of non-neutralizing anti-MAYV mAbs
C57BL/6J mice were inoculated with the MAYV strain CH and
boosted twice with recombinant MAYV E2 ectodomain protein
(amino acids 1–340) in Freund’s incomplete adjuvant. Three
days after the second booster immunization, we performed a
splenocyte-myeloma fusion to generate hybridomas (Earnest
et al., 2019; Pal et al., 2013). We isolated 114 mAbs that bound
to the MAYV E2 protein by ELISA. To identify mAbs that more
broadly recognized MAYV, we also assessed binding to Vero
cells infected with the heterologous MAYV strain BeH407 (96%
amino acid identity in E2-E1) by flow cytometry. We successfully
cloned 73 hybridomas with these features. Because previous
studies demonstrated that IgG2a/c isotypes exhibited superior
protective activity against alphaviruses (Earnest et al., 2019;
Pal et al., 2013), we isotyped the clones and selected 13 IgG2c
mAbs for further characterization.
The 13 mAbs were purified and evaluated for neutralizing ac-
tivity by using focus reduction neutralization tests (FRNTs) in
Vero and C2C12 myoblast cells. Serial dilutions of mAb were
mixed with 102 focus-forming units (FFUs) of MAYV-BeH407
before incubation with the two target cells. In contrast to a pre-
viously described neutralizing mAb (MAY-117; Earnest et al.,
2019), none of the 13 mAbs showed measurable inhibitory
activity in either Vero or C2C12 cells even at concentrations of
50 mg/ml (Figures 1A and 1B).
We next evaluated these mAbs for binding to MAYV virions
(Figure 1C) and recombinant E2 protein (Figure 1D). Half-
maximal binding (EC50) to virions was measured by ELISA after
MAYV was captured with an anti-MAYV mAb containing a hu-
man Fc region. A neutralizing anti-MAYV E2 B domain mAb
(MAY-117) (Earnest et al., 2019) was used for comparison. All
13 mAbs bound to intact virions with EC50 values ranging from
4 to 379 ng/ml, with 9 of 13 having EC50 values less than
100 ng/ml (Table 1). The EC50 values, however, were 10-fold
higher than those for MAY-117 (0.5 ng/ml). The maximal binding
values (Bmax) generally were consistent among the mAbs, with
the majority showing optical density (OD) values between 1.7
and 2.8. However, MAY-39 and MAY-112 had maximal OD
values of <1, which suggests that fewer mAbs can bind the virus
at saturation (Table 1; Figure S1A). ELISA-based competition
binding studies for MAYV virions revealed six distinct groups
(Figure 1E). The majority of anti-MAYV mAbs also bound the re-
combinant E2 protein in an ELISA, although the EC50 values
generally were higher than that observed for virion binding, sug-
gesting less avid binding to recombinant protein than intact vi-
rions (Table 1). Furthermore, MAY-39 and MAY-112 did not
bind appreciably to solid phase recombinant E2 protein by
ELISA. The disparities in binding to recombinant protein versus
intact virion may reflect differences in epitope presentation or
engagement of a quaternary epitope between or across E2 pro-
teins within a spike, which is present exclusively on the virion, as
seen with anti-CHIKV (Fox et al., 2015) and anti-RRV (Powell
et al., 2020) mAbs. As all of the non-neutralizing mAbs bound
E2 after western blotting when we used both non-reducing and
reducing conditions, they likely do not recognize conformational
epitopes (Figure S1B). To acquire more quantitative data, we
measured monovalent binding affinities to the MAYV E2 protein
by biolayer interferometry (BLI) (Table 1; Figure S1C). The
measured kinetic binding constant (KD) rate for the mAbs varied
by more than 100-fold from 4 to 548 nM, with the affinity of bind-
ing correlating inversely with the half-life (t1/2). MAY-10, MAY-
108, MAY-8, and MAY-23 showed the highest affinities with KD
values of <19 nM and t1/2 values over 130 s. MAY-60, MAY-68,
and MAY-112 showed no appreciable binding.
Epitope mapping of anti-MAYV mAbs
Although our ELISA, BLI, andwestern blotting data establish that
the non-neutralizing mAbs recognize the MAYV E2 glycoprotein,
we observed no binding to the recombinant E2 B domain (J.T.E.
and M.S.D., unpublished data). To test whether the mAbs bound
to regions in the A domain, we performed alanine scanningmuta-
genesis in the context of expression of the structural polyprotein
(C-E3-E2-6K-E1). Based on the CHIKV pE2-E1 structure (PDB:
3N42), we introduced alanine substitutions in predicted sol-
vent-exposed amino acids of the A domain and the b-ribbon
arch connecting the A and B domains (residues 1–172) of the
MAYV E2 protein. When an alanine was present in the viral
sequence, we substituted a serine residue. 293T cells were
transfected with wild-type (WT) or individual mutant plasmids,
and mAb binding was measured by flow cytometry. An oligoclo-
nal pool of the 13mAbs aswell asMAY-117, an anti-E2 B domain
mAb, was used to control for mutant protein expression. Key
interaction residues were defined when mAb binding to a given
mutant was %25% after normalization of binding to cells ex-
pressing the WT plasmid (Table S1). The 13 mAbs mapped to
6 different sites within or near the A domain (Figure 2A), which
correlated with the following competition groups (Figure 1E):
group A, residues 27–29 (Figure S2A); group B, residues 57–61
(Figure S2B); group C, residues 72–77 (Figure S2C); group D,
residues 81–86 (Figure S2D); group E, residues 159–163




(Figure S2E); and group F, residues 168–173 (Figure S2F). Group
D mAbs, which had the largest number in our panel, map to an
epitope facing the inside of the E2-E1 trimer (Figures 2B and
2C); mutation of these residues resulted in loss of binding of
MAY-27, MAY-39, MAY-41, MAY-68, and MAY-112. Two mAb
groups map to sites adjacent to the A domain in the b-ribbon
arch connecting the A and B domains of E2 (159–163, group E,
MAY-102 and MAY-108; and 168–173, group F, MAY-72).
MAY-23, the lone member of group A, localizes to a b strand
adjacent to the N-terminal linker on the outer face of the E2-E1
trimeric complex (Figure 2C). The group B (MAY-8 and MAY-
10) and C (MAY-1 and MAY-60) mAbs map to two structurally
Figure 1. Binding of non-neutralizing anti-
MAYV mAbs to virions and recombinant E2
protein
(A and B) Anti-MAYV mAbs were tested for
neutralization of MAYV on Vero (A) and C2C12
myoblast (B) cells. Serial dilutions of the indicated
mAbs were incubated with 102 FFU of MAYV-
BeH407 and then added to the indicated cells. Viral
foci are plotted relative to a no mAb control. The
neutralizing mAb MAY-117 was used as a positive
control, and an irrelevant mIgG2c mAb was used
as a negative isotype control (mean and SD of two
experiments performed in triplicate).
(C and D) Binding to MAYV virions (C) or recom-
binant MAYV E2 protein (D) by ELISA. Virions were
captured with a humanized mAb to MAYV, and
recombinant MAYV E2 protein was bound directly
to microtiter plates. Bound murine mAbs were
detected with an horseradish peroxidase (HRP)-
conjugated secondary antibody. Data are ex-
pressed as OD values relative to the 10-mg/ml
sample (mean and SD of two experiments per-
formed in triplicate).
(E) MAYV mAbs were competed for binding to
MAYV (strain BeH407) by ELISA. Virus was
captured on plates using a humanized anti-MAYV
mAb. Captured virion was incubated with 10 mg/ml
of the indicated mAb (first antibody). Antibody-vi-
rus complexes were incubatedwith 10 ng/ml of the
indicated mAb labeled with biotin (second anti-
body). Binding was detected using streptavidin
HRP and is indicated by color from high (red) to low
(blue). Data are presented relative to a control with
no first antibody and are representative of two
experiments.
adjacent regions near the top of the spike
complex (Figures 2B and 2C). As non-
neutralizing anti-MAYV mAbs recognize
denatured forms of E2 (Figure S1B) and
their mapping residues cluster together,
these antibodies likely preferentially
engage linear peptide epitopes.
Protection against lethal MAYV
challenge by mAbs
We tested the 13 non-neutralizing mAbs
in a lethal MAYV challenge model in
4-week-old female C57BL/6J mice.
Because MAYV does not cause mortality in immunocompetent
mice, we treated animals with 100 mg of an anti-Ifnar1 mAb
(MAR-5A3; Sheehan et al., 2006) to transiently immunosuppress
them. Mice given anti-Ifnar1 mAb succumbed to subcutaneous
inoculation of 103 FFU of MAYV-BeH407 between 3 and
5 days post-infection (dpi) (Figure 3). To assess for protection
as prophylaxis in this model, mice were treated with a single
100-mg (5 mg/kg) dose of individual anti-MAYV mAbs 1 day
before virus inoculation. We observed a range of protective ac-
tivity of the mAbs, as follows: MAY-10 and MAY-108 conferred
100% protection (Figure 3A); MAY-23, MAY-8, and MAY-102
protected R50% of mice from lethality; and MAY-1, MAY-39,




MAY-60, MAY-68, MAY-72, andMAY-112 exhibited less protec-
tive activity (30%–40%) (Figure 3B).MAY-27 andMAY-41 had no
significant protective activity. Notably, the in vivo activity of the
non-neutralizing antibodies generally correlated with binding af-
finity, with the most protective mAbs having lower KD and higher
t1/2 values (Table 1). Moreover, the most protective mAbsmap to
one of two epitopes, as follows: group B mAbs localize to an
epitope at the top of the spike trimer (MAY-10 and MAY-8; Fig-
ures 2B and 2C), and group E mAbs engage an epitope in the
linker region between the A and B domains on the side of the
spike trimer (MAY-23, MAY-102, and MAY-108; Figures 2B
and 2C). These results suggest both binding affinity and epitope
location facilitate optimal protection by non-neutralizing mAbs.
We previously described a protective neutralizing anti-MAYV
mAb (MAY-134) that maps to the B domain of E2 (Earnest
et al., 2019). Because MAY-134 is protective and does not
compete for binding with either MAY-10 or MAY-108 (Figure S3),
we tested whether combinations of neutralizing (MAY-134) and
non-neutralizing (MAY-10 or MAY-108) mAbs could enhance
therapeutic efficacy in our lethal challenge mouse model. We
administered 200 mg (10 mg/kg) of either MAY-10 (Figure 3C),
MAY-108 (Figure 3D), or MAY-134 (Figures 3C and 3D) or
100 mg each of MAY-10 or MAY-108 and MAY-134 2 days after
mice were inoculated with 103 FFU of MAYV-BeH407. Although
we observed no statistically significant protection from lethal
challenge inmice treated with any single mAb, combination ther-
apy with MAY-10 and MAY-134 or MAY-108 and MAY-134 pro-
tected 60% and 50% of mice, respectively (Figures 3C and 3D).
Thus, non-neutralizing A domain and neutralizing B domain
mAbs together provide greater protection as post-exposure
therapy than either mAb alone.
Antibody protection in vivo requires Fc effector
functions
We hypothesized that protection by non-neutralizing mAb might
require Fc effector functions. To test this idea, we repeated pas-
sive transfer experiments in anti-Ifnar1-mAb-treated C57BL/6J
mice lacking the common signaling gamma (g) chain and expres-
sion of activating FcgR (FcgR/). These mice were treated with
a single 100-mg dose of MAY-10 or MAY-108 1 day prior to sub-
cutaneous inoculation with MAYV-BeH407. Remarkably, both
isotype control and anti-MAYV (MAY-10 or MAY-108)-treated
FcgR/ mice uniformly succumbed by 4 dpi (Figure 4A), which
contrasts with results seen in congenic WT C57BL/6J mice
(Figure 3A).
To corroborate the role of Fc effector function in the protective
activity of non-neutralizing anti-MAYVmAbs, we engineered iso-
type-switched versions of MAY-10 and MAY-108. Murine IgG2c
(mIgG2c) antibodies bind mouse Fc gamma receptor (FcgR)I
and FcgRIV with high and moderate affinity, whereas murine
IgG1 (mIgG1) binds less avidly to these receptors (Mancardi
et al., 2008). Furthermore, human IgG1 (hIgG1) binds strongly
to these murine FcgRs in a manner similar to mIgG2c (Dekkers
et al., 2017; Earnest et al., 2019). We cloned the variable regions
of MAY-10 and MAY-108 into antibody expression constructs
with Fc regions of mIgG1 or hIgG1. Additionally, we introduced
an N297Qmutation in the Fc region of the hIgG1 construct to re-
move an N-linked glycan that is necessary for Fc-FcgR interac-
tions (Tao and Morrison, 1989).
We first tested whether the isotype-switched MAY-10 and
MAY-108 had different binding patterns to recombinant murine
FcgRs (I, III, and IV) by ELISA. As expected, mIgG1 mAbs
showed less binding to all of the tested FcgRs (Figure 4B).
hIgG1 mAbs showed slightly lower binding, but it was more
similar to mIgG2c than mIgG1. The N297Q variant lost 90%
of binding activity compared to mIgG2c. We confirmed that
the isotype-switched MAY-10 and MAY-108 mAbs bound
MAYV virions similarly (Figures 4C and 4E), and thus, altering
Fc interactions did not affect antibody-antigen binding. We
administered a single 100-mg dose of the isotype-switched
mAbs to anti-Ifnar1-mAb-treated WT C57BL/6J mice 1 day
before subcutaneous inoculation of MAYV. As expected,
mIgG2c MAY-10 and MAY-108 protected mice from lethal
challenge. Similarly, hIgG1 mAbs protected 90% (MAY-10)
and 100% (MAY-108) of mice from mortality. In contrast, the
mIgG1 and aglycosyl hIgG1-N297Q forms of MAY-10 and
MAY-108 lost activity (Figures 4D and 4F). Collectively, these
experiments establish that protection against lethal challenge















0.4 (0.3–0.5) 0.4 (0.3–0.5) 2.84 9.2 264.1
10 12 (8–17) 302 (274–334) 1.66 14.0 231.8
108 10 (5–23) 82 (72–95) 2.65 4.1 213.9
8 5 (3–7) 195 (157–242) 1.22 16.6 136.3
23 21 (14–31) 41 (36–45) 2.04 18.4 142.6
102 83 (61–113) 461 (406–523) 2.06 211.3 61.5
60 45 (28–75) 84 (77–92) 1.90 ND ND
1 4 (2–6) 5 (4–6) 2.79 160.0 14.1
41 25 (19–33) 863 (773–997) 1.99 47.3 92.5
27 56 (41–75) 344 (317–374) 1.72 110.5 12.6
39 332 (238–463) >1,000 0.80 547.6 74.5
68 100 (71–138) 383 (333–440) 2.00 ND ND
72 134 (79–225) 33 (16–68) 2.04 165.6 14.9
112 379 (230–637) >1,000 0.88 ND ND
Anti-MAYV mAbs were measured for binding to intact MAYV virions by
capture ELISA and recombinant MAYV E2 protein by ELISA and BLI.
Effective concentration of 50% binding (EC50) was calculated from the
OD values with serial dilutions of the indicated mAb. Bmax was measured
as the highest OD value observed in the virion capture ELISA. BLI was
performed by binding biotinylated mAbs to streptavidin-coated pins
and flowing over recombinant E2 protein. The equilibrium binding con-
stant (KD) and half-life (t1/2) of antibody binding were measured. The pre-
viously characterized (Earnest et al., 2019) positive-control MAY-117
mAb is listed first for comparison, and subsequently, mAbs are arranged
from most to least protective. MAY-10, MAY-108, MAY-8, MAY-23, and
MAY-102mAbs hadR50%protection in the lethal challengemodel. Data
are the mean of two independent experiments, and 95% confidence in-
tervals are in parentheses. ND, not determined due to poor binding.




by non-neutralizing anti-MAYV mAbs requires Fc-effector-
function-dependent activity.
Protection against MAYV-induced musculoskeletal
disease by mAbs
We assessed the activity of our twomost protective non-neutral-
izing mAbs in a more physiologically relevant model of MAYV-
induced disease. Subcutaneous inoculation of MAYV in the
foot of immunocompetent C57BL/6J mice results in joint
swelling and musculoskeletal disease (Earnest et al., 2019). Viral
infection is first observed in the ipsilateral foot, ankle, and calf
muscle before disseminating to the contralateral extremity. Simi-
larly, foot swelling occurs first in the ipsilateral ankle and later in
the contralateral ankle (Earnest et al., 2019). We treated C57BL6/
Jmicewith a single 100-mg dose ofMAY-10,MAY-108, or an iso-
type control mAb before subcutaneous inoculation of MAYV in
the foot. At 1 and 7 dpi, animals were euthanized and perfused
extensively with PBS. The ipsilateral ankle and calf muscle,
contralateral ankle and calf muscle, and spleen were harvested,
and viral RNA levels were measured using quantitative reverse-
transcriptase PCR (qRT-PCR) with probes targeting the 50 un-
translated region of MAYV (Waggoner et al., 2018). At 1 dpi,
we observed a >1,000-fold reduction in MAVY RNA in the ipsilat-
eral ankles of both MAY-10- and MAY-108-treated mice
compared to the isotype control mAb (Figure 5A). Moreover,
we observed dissemination of MAYV to the ipsilateral calf mus-
cle, the contralateral leg, and the spleen in isotype mAb treated
mice, but there was no detectable viral RNA in mice treated with
the non-neutralizingmAbsMAY-10 orMAY-108 (Figures 5B–5E).
Remarkably, at 7 dpi, MAY-10- and MAY-108-treated mice had
cleared viral RNA levels from the ipsilateral foot, mice showed no
infection of the contralateral extremity, and only one animal had
detectable viral RNA in the spleen (Figures 5F–5J).
We next tested whether antibody effector functions were
required to limit viral infection and control musculoskeletal dis-
ease in immunocompetent mice by treating WT C57BL/6J
mice with MAY-10-hIgG1 or aglycosyl MAY-10-hIgG1-N297Q
1 day before MAYV infection. At 7 dpi, the humanized version
of MAY-10 protected mice from virus infection (Figures 5K–5O)
to a similar extent as the parental mouse mAbs (Figures 5F–
5J), with decreases in all tissues measured when compared to
isotype control mAb. However, MAY-10-hIgG1-N297Q did not
provide virological protection in this model. We also observed
Fc-effector-function-dependent decreases in the inflammatory
cytokines (tumor necrosis factor a [TNF-a], CXCL1, CXCL9,
CXCL10, CCL3, CCL4, CCL5, and CSF1) in the ipsilateral ankles
of MAY-10-hIgG1-treated animals at 7 dpi (Figure S4). These
data indicate that the effector functions of non-neutralizing
mAbs are required for efficient viral clearance and reduction of
inflammation in joint-associated tissues of infected animals.
To determine if the mAbs protect against MAYV-mediated
musculoskeletal disease, we measured ankle swelling. We
Figure 2. Mapping of mAbs to MAYV E2 protein
(A) Heatmap of relative binding of anti-MAYVmAbs toMAYV-E2 A domainmutants. 293T cells were transfected with a C-E3-E2-6K-E1 plasmid containing alanine
mutations in the A domain of E2. Binding of the indicated mAbs were measured by flow cytometry; the full dataset is shown in Table S1 and Figure S2. Relative
binding compared to an oligoclonal control is indicated by color from high (red) to low (blue).
(B and C) Residues required for mAb engagement are depicted as balls and sticks on a ribbon diagram of the predicted structure of MAYV E2-E1 monomer
generated using Phyre2 (B) and are highlighted on the monomers arranged as a trimeric spike (C). The E1 and E2 glycoproteins are light and dark gray,
respectively. Within E2, domain A is cyan, the b-ribbon is dark cyan. In the surface representation (C), the A domain and b-ribbon regions are outlined in red and
yellow, respectively. Competition groups are color coded as follows: group A, dark pink (residues 27–29); group B, orange (57–61); groupC, blue (72–77); group D,
dark green (81–86); group E, lavender (159–163); group F, light green (168–173); and the anti-B domain control mAb MAY-117, bright yellow (181–186). See also
Table S1 and Figure S2.




observed substantial swelling in the ipsilateral ankle from 2–10
dpi (Figure 5K) and the contralateral ankle from 6–8 dpi (Fig-
ure 5L) in mice treated with an isotype control mAb, whereas an-
imals treated with MAY-10 or MAY-108 showed no ankle
swelling. Antibody-mediated protection was Fc effector function
dependent, as MAY-10-hIgG1, but not MAY-10-hIgG1-N297Q,
limited swelling in this model (Figure 5R). Thus, even without
neutralizing activity, anti-MAYV mAbs can prevent dissemina-
tion, clear infection, and limit musculoskeletal disease in immu-
nocompetent mice.
Myeloid-cell-dependent protection of non-neutralizing
mAbs
Because non-neutralizingmAbs control MAYV infection in an Fc-
effector-function-dependent manner, we hypothesized that
specific immune cells bearing FcgRs mediate this protection
(Bournazos et al., 2015; Lu et al., 2018). Previous studies have
shown that monocytes and natural killer (NK) cells mediate anti-
body-dependent antiviral protection in vivo by antibody-depen-
dent cellular cytotoxicity (ADCC), antibody-dependent cellular
phagocytosis (ADCP), or antibody-dependent virus opsonization
(Lu et al., 2018). To determine the cell type responsible for
antibody-dependent protection against MAYV, we depleted
monocytes or NK cells with specific mAbs (anti-CCR2 and
anti-NK1.1, respectively) beginning 1 day before infection using
the anti-Ifnar1-mAb-treated immunocompromised lethal chal-
lenge mouse model. As expected, we observed complete pro-
tection against mortality in mice treated with MAY-10 or MAY-
108 in the absence of immune-cell-depleting antibody (Figures
6A and 6B). However, in the presence of anti-CCR2 mAb treat-
ment and monocyte depletion (Figure S5A), MAY-10 and MAY-
108 protection decreased to 40% and 30%, respectively.
When similar depletion experiments were performed with anti-
NK1.1 mAb to deplete NK cells (Figure S5B), we saw no change
in protective activity in MAY-10 or MAY-108 (Figure 6B). These
data suggest that CCR2+ monocytes are principally responsible
for the protection conferred by non-neutralizing anti-MAYV
mAbs.
We evaluated how monocytes might contribute to antibody-
mediated protection. To assess whether non-neutralizing anti-
MAYV mAbs promote opsonization of free virions and clearance
by monocytes, we performed in vitro binding assays in the foll-
lowing two murine myeloid cell lines: microglial-derived BV2
cells (Figures 6C, 6D, 6G, and 6H) and bone-marrow-derived
monocytic LADMAC cells (Figures 6E, 6F, 6I, and 6J). Although
LADMAC cells are essentially non-permissive for MAYV infection
unless the Mxra8 receptor is ectopically expressed (Zhang et al.,
2018), BV2 cells can be infected at low levels because they ex-
press heparin sulfate (HS) as an attachment factor. To minimize
the effects of HS on MAYV binding and infection of BV2 cells,
we used BV2 cells lacking b-1,4-galactosyltransferase 7
(BV2-Db4galt7) (Ma et al., 2020), a key enzyme required for
glycosaminoglycan synthesis. Flow cytometry analysis showed
that BV2 cells express high levels of FcgRI, FcgRII, FcgRIII,
and FcgRIV on their surface, whereas LADMAC cells express
FcgRI, FcgRII, and FcgRIV and at lower levels (Figure S6).
We performed two sets of experiments, namely, an antibody-
dependent virus depletion assay from the supernatant (Figures
6C–6F) and cell binding/internalization assays (Figures 6G–6J).
For the virus depletion assay, 103 FFU of MAYV was pre-incu-
bated with serial dilutions of the hIgG1 variant of MAY-10,
MAY-108, or isotype control mAb before being added to
BV2-Db4galt7 or LADMAC cells. After a 30-min incubation at
37C, the supernatant containing unbound virus was collected,
and after virion lysis, viral RNA was measured by qRT-PCR. Viral
RNA levels were compared with a standard curve generated
from known quantities of infectious MAYV to determine viral
equivalents per ml. Notably, less viral RNA remained in the su-
pernatant after treatment with MAY-10 (Figures 6C and 6E)
and MAY-108 (Figures 6D and 6F) than that with the isotype
Figure 3. Antibody protection against lethal
MAYV challenge
Four-week-old C57BL/6J female mice were
treated with 100 mg of anti-Ifnar1 mAb 1 day before
subcutaneous inoculation of MAYV-BeH407.
(A and B) A single 100-mg dose of anti-MAYVmAbs
was administered by intraperitoneal injection 1 day
before virus inoculation. The mAbs exhibited a
range of activity with some showing >50% pro-
tection (A) and others <50% (B). Data are from two
experiments.
(C and D) Combination therapy of an anti-MAYV E2
B domain mAb (MAY-134) and anti-MAYV E2 A
domain mAbs. C57BL6/J mice were treated with
100 mg of anti-Ifnar1 mAb 1 day before subcu-
taneous virus inoculation. (C) Two days after
infection, micewere treatedwith 200 mg ofMAY-10
or MAY-134 or 100 mg each of MAY-10 and MAY-
134. (D) Two days after infection, mice were
treated with 200 mg of MAY-108 or MAY-134 or
100 mg each of MAY-108 and MAY-134 (two ex-
periments, n = 8; *p < 0.05; **p < 0.01; ***p < 0.001;
****p < 0.0001; log-rank test with Bonferroni
correction compared to isotype control mAb). See
also Figure S3.




Figure 4. Protection by non-neutralizing mAbs is Fc dependent
(A) Four-week-old C57BL/6J FcgR/male and female mice were administered 100 mg of MAY-10 or MAY-108 1 day before subcutaneous inoculation of MAYV-
BeH407 (two experiments, n = 6).
(B) Isotype-switched mAb binding to recombinant murine FcgRI, FcgRIII, and FcgRIV. MAY-10 or MAY-108 of the indicated isotype were added to plates coated
with FcgRs. Binding data: two-way ANOVA with Sidak’s post-test, compared to mIgG2c isotype mAb.
(C–F) MAY-10 (C) and MAY-108 (E) were isotype switched from murine IgG2c to murine IgG1, human IgG1, or human IgG1-N297Q. Each antibody variant was
tested for binding to captured MAYV by ELISA. For protection studies (D and F), 100 mg of the indicated mAb was administered to 4-week-old C57BL/6J mice
1 day before subcutaneous inoculation with MAYV (two experiments, n = 6; log-rank test with Bonferroni correction compared to isotype control mAb). *p < 0.05;
**p < 0.01; ***p < 0.001; ****p < 0.0001.




Figure 5. Antibodies clear MAYV, prevent viral dissemination, and protect against musculoskeletal disease
(A–J) Tissue titers of MAYV at 1 (A–E) or 7 (F–J) dpi. Four-week-old C57BL/6J mice treated with 100 mg of MAY-10, MAY-108, or an isotype control mAb 1 day
before subcutaneous inoculation with MAYV-BeH407. At the indicated days, the ipsilateral ankle (A and F), ipsilateral calf muscle (B and G), contralateral ankle
(C and H), contralateral calf muscle (D and I), and spleen (E and J) were harvested, and viral RNA was measured (two experiments; n = 6, one-way ANOVA with
Dunnett’s post-test).
(K–O) Tissue titers of mice treated with 100 mg of MAY-10-hIgG1 or MAY-hIgG1-N297Q 1 day before infection. MAYV titers in the ipsilateral ankle (K) and calf
muscle (L), the contralateral ankle (M) and calf muscle (N), and the spleen (O) were measured at 7 dpi (three experiments; n = 11, one-way ANOVA with Dunnett’s
post-test).
(P–R) Four-week-oldC57BL/6Jmicewere treatedwithMAY-10 orMAY-108 and infected as described above. Ipsilateral (P) and contralateral (Q) ankle joints were
measured using digital calipers. (R) Ipsilateral ankle swelling was measured in mice treated with MAY-10-hIgG1 or MAY-10-hIgG1-N297Q (mean and SD of two
experiments; n = 10, two-way ANOVA with Tukey’s post-test). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. See also Figure S4.




Figure 6. Protection by non-neutralizing mAbs depends on monocytes
(A) Four-week-old C57BL6/J mice were treated with 100 mg of anti-Ifnar1 mAb and 100 mg of MAY-10, MAY-108, or isotype control mAb 1 day before infection
with MAYV-BeH407. Indicated mice also were treated with 25 mg of an anti-CCR2 mAb at 1 day before infection and every other day after (two experiments,
n = 10; log-rank test with Bonferroni correction).
(B) NK cells were depleted by treatingmicewith 200 mgmAb of anti-NK1.1mAb 1 day before infection and every other day after. Mice were treatedwith anti-Ifnar1
mAb and MAY-10, MAY-108, or isotype control mAb as above (two experiments, n = 10; log-rank test with Bonferroni correction).
(C–J) Antibody-mediated binding of hIgG1 variants of MAYV to BV2-Db4galt7 (C, D, G, andH) or LADMAC (E, F, I, and J) cells. Virus binding to cells wasmeasured
indirectly by the depletion of MAYV from supernatants (C–F) or by direct binding and/or internalization of target cells (G–J). For measuring supernatants, MAYV
was incubated with the indicated amount of hIgG1 variants of MAY-10 (C and E) or MAY-108 (D and F) for 1 h at 37C before adding to the indicated cell for 30min
at 37C. Viral RNA from supernatants wasmeasured. Isotype-matched antibodies and hIgG1-N297QmAb variants served as negative controls. Tomeasure virus
binding and internalization, BV2-Db4galt7 or LADMAC cells were inoculated withMAYV that had been pre-incubated withMAY-10 (G and I) or MAY-108 (H and J).
After incubating for 30 min at 37C, cells were washed with PBS and lysed, and viral RNA was measured.
(legend continued on next page)




control mAb. Viral clearance from the supernatant occurred dose
dependently and required Fc effector functions, as it was not
observed with the aglycosyl hIgG1-N297Q variants of MAY-10
and MAY-108. We observed similar results with the mouse
IgG2c versions of both MAY-10 and MAY-108 (Figures S7A–
S7D). These data suggest that the Fc region of anti-MAYV
mAbs promotes clearance of MAYV virions from the inoculum,
presumably by binding FcgR on the myeloid cells.
To test this hypothesis directly, we performed cell binding and
internalization assays (Figures 6G–6J, S6, and S8). MAYV was
incubated with MAY-10, MAY-108, or isotype control mAb for
30 min at 37C. Antibody-virion complexes then were added to
BV2-Db4galt7 or LADMAC cells and incubated for 1 h at 37C.
Cells then were rinsed thoroughly with PBS and lysed, and
attached and/or internalized viral RNA was measured by qRT-
PCR. Pre-treatment of MAYV with MAY-10 and MAY-108 signif-
icantly increased the level of cell-associated viral RNA compared
to the isotype control mAb. Antibody-dependent binding and/or
internalization of MAYV virions by BV2-Db4galt7 or LADMAC
cells occurred dose dependently and required a functional Fc re-
gion, as no increasewas observedwith the aglycosyl N297Q var-
iants of MAY-10 andMAY-108. For the highest concentrations of
MAY-10 and MAY-108, we observed a >100-fold increase in
cell-associated viral RNA compared to the isotype control
mAb. Similar data were observed using mouse IgG2c versions
of MAYV antibodies (Figures S7E–S7H). Treatment of
BV2-Db4galt7 or LADMAC cells at 1 h after 37C incubation
with proteinase K and RNase A, to remove bound but not inter-
nalized virus, revealed that a significant fraction of opsonized
MAYV transited into the cells (Figure S8). Collectively, these
data suggest that antibody-dependent binding to MAYV in
myeloid cells was dependent on Fc-FcgR interactions, resulted
in enhanced cell binding and uptake, and was not due to virion
cross-linking and aggregation, as seen for some anti-alphavirus
antibodies (Zhou et al., 2020).
We next evaluated if MAYV association with target FcgR-ex-
pressing myeloid cells resulted in abortive or productive (and
possibly even antibody enhanced) infection. We used both
permissive WT BV2 (Figures 6K and 6L) and non-permissive
BV2-Db4galt7 (Figures 6M and 6N) cells to track viral infection
in the presence and absence of non-neutralizing mAbs. MAYV
was incubated with serial dilutions of MAY-10 (Figures 6K and
6M) or MAY-108 (Figures 6L and 6N) to form antibody-antigen
complexes. These complexes were added to target cells for a
1-h incubation at 37C, and the cells then were rinsed to remove
unbound virus. The cells were lysed either immediately after
rinsing (1 h post-infection [hpi]) or after another 7 h-incubation
at 37C (8 hpi), and cell-associated viral RNA was measured
by qRT-PCR. As expected, we observed an initial increase in
cell-associated viral RNA at 1 hpi when the virions were pre-
treated with the mIgG2c but not N297Q forms of MAY-10 and
MAY-108. For the WT BV2 cells (Figures 6K and 6L), we
observed a10,000-fold increase in viral RNA at 8 hpi compared
to 1 hpi with the isotype-mAb-treated virions, which indicates
thatMAYV replicated in the BV2 cells. However, therewas no dif-
ference in viral RNA levels at 8 hpi between anti-MAYV and iso-
type mAb treatments, indicating that the greater level of virus
binding and internalization at 1 hpi caused by non-neutralizing
mAbsMAY-10 andMAY-108 did not result in enhanced infection
in WT BV2 cells. To determine if mAb-induced virion binding and
internalization caused enhancement of infection of non-permis-
sive myeloid cells (as seen with dengue virus [Brandt et al.,
1982; Halstead et al., 1980]), we repeated experiments in the
non-permissive BV2-Db4galt cells (Figures 6M and 6N). We
observed the expected increase in cell-associated viral RNA at
1 hpi, and clearance was observed at 8 hpi with no evidence of
productive infection. We observed similar results by using
mIgG2c versions of the anti-MAYV mAbs (Figures S7I–S7L). To
determine if BV2 cells are even capable of antibody-dependent
enhancement (ADE), we repeated the experiments with Zika vi-
rus (ZIKV), a flavivirus whose infection is enhanced in myeloid
cells by cross-reactive, non-neutralizing antibodies (Castanha
et al., 2017; Dejnirattisai et al., 2016). We incubated a mouse-
adapted ZIKV virus (Gorman et al., 2018) with serial dilutions of
themAb E60, a poorly neutralizingmAb that binds the conserved
fusion loop of the flavivirus E protein (Oliphant et al., 2006).
Despite not observing ADE with MAYV, we observed robust
ADE with ZIKV and the E60 mAb in BV2 and LADMAC cells
(Figures S7M–S7O), suggesting the outcome of antibody
engagement in cells expressing FcgRs is virus specific. In the
case of MAYV, non-neutralizing mAbs facilitate the interaction
of virions with myeloid cells that results in abortive infection
and clearance.
DISCUSSION
Previous studies have analyzed the importance of neutralizing
antibody responses in protecting against alphavirus infection.
These studies highlighted both the effects of virus neutralizing
activity (Earnest et al., 2019; Fox et al., 2015; Jin et al., 2015,
2018; Martins et al., 2019; Pal et al., 2013) and Fc effector func-
tions (Earnest et al., 2019; Fox et al., 2019) for optimal in vivo ac-
tivity. However, they could not fully gauge the protective activity
of Fc effector functions because the antibodies were inherently
neutralizing. Here, we identified a panel of 13 anti-MAYV mAbs
that bind avidly to virions and infected cells yet exhibit no detect-
able neutralizing activity against the virus in Vero and C2C12
cells. Passive transfer of non-neutralizing mAbs conferred signif-
icant protection in vivo that was completely dependent on Fc
effector interactions, as determined using IgG subclass switch
variants and N297Q variants lacking the ability to engage FcgRs.
The mIgG2c mAbs that we characterized exhibited a range of
protective ability in the lethal MAYV challenge model. The rea-
sons for these differences may be due to several factors. We
observed variable binding to MAYV virions in a capture ELISA
experiment and to recombinant E2 protein by using ELISA and
(K–N) Antibody-dependent infection assays. Serial dilutions of hIgG1mAbs were pre-incubated with MAYV before being added to permissive BV2 cells (K and L)
or non-permissive BV2-Db4galt7 cells (M and N). Binding and internalization into cells was measured as above (G–H) at 1 or 8 hpi after removal of unbound virus
(mean and SD of three experiments performed in triplicate; one-way ANOVAwith Dunnett’s post-test compared to the isotypemAb control). *p < 0.05; **p < 0.01;
***p < 0.001; ****p < 0.0001. See also Figures S5–S8.




BLI experiments. ThemAbs that boundmost avidly to virions and
recombinant E2 proteins showed the greatest protective activity
in vivo. Indeed, MAY-10 and MAY-108, our most protective
mAbs, had KD values that were 100-fold lower and had substan-
tially longer binding t1/2 than many poorly protecting mAbs. A
higher level of virus binding likely enhances the Fc-dependent
clearance by myeloid cells. Furthermore, the most protective
mAbs map to two epitopes within or proximal to the A domain,
as follows: one near the amino terminus on the top of the spike
trimeric complex (group B), and a second in the b-ribbon region
on the outer face of the E2-E1 spike (group E). Possibly, the
mAbs binding these regions of the E2 protein are more acces-
sible for engagement by FcgRs on monocytes, enabling virus
clearance and protection. The orientation of mAb binding to
the virion also could affect presentation of the Fc region to
FcgRs, as was seen with anti-dengue virus mAbs (Renner
et al., 2018).
Our non-neutralizing antibodies bound to six distinct regions
of the MAYV E2 A domain and the b-ribbon region between the
A and B domains. In comparison, other mAbs against arthito-
genic alphavirues (e.g., CHIKV) that map to epitopes within
the A domain can be potently neutralizing. The anti-CHIKV hu-
man mAbs 1H12 and 3N23 are potently inhibitory in cell culture
and yet share interaction residues with group B and C mAbs
from our panel (Smith et al., 2015). Similarly, the highly neutral-
izing anti-CHIKV mAbs 4J21 and 5M16 (Long et al., 2015) bind
amino acids shared by group B and F mAbs as well as others
throughout the A and B domains. The distinguishing feature of
these neutralizing mAbs is their ability to bind residues within
multiple E2 domains (e.g., A and B) or across different E2 pro-
teins, whereas the majority of the non-neutralizing mAbs
appear to recognize linear determinants. Engagement of ter-
tiary and quaternary epitopes within and across E2 may be
required for alphavirus neutralization. Indeed, structural studies
have demonstrated cross-linking of multiple distinct domains in
E2 by potently neutralizing mAbs (Fox et al., 2015; Powell et al.,
2020).
We found that monocytes were necessary for antibody-
effector-mediated protection from MAYV infection. Our
in vitro studies suggest a possible mechanistic basis for at
least part of the inhibitory activity. Non-neutralizing anti-
MAYV mAbs bind virus and facilitate clearance by Fc-depen-
dent internalization and destruction in myeloid cells. This
abortive infection mechanism explains how non-neutralizing
mAbs could prevent dissemination from the site of inoculation
but might not explain how antibodies effectively clear MAYV-
infected cells. Additionally, monocytes might clear virus from
infected cells by ADCP (Bournazos et al., 2015; Lu et al.,
2018) because the viral E1 and E2 structural proteins are dis-
played on the plasma membrane surface prior to virion
morphogenesis and budding and can be recognized by anti-
bodies. Alternatively, the enhanced entry of virus into myeloid
cells in an antibody- and Fc-dependent manner could promote
antigen cross-presentation and accelerated CD8+-T-cell-
mediated clearance (Bournazos et al., 2020a; Platzer et al.,
2014). ADCC by NK cells did not appear to have a dominant
role in protection by non-neutralizing mAbs, as depletion did
not impact survival.
Under certain circumstances, monocytes themselves can be
infected by alphaviruses (Her et al., 2010; Winkler et al., 2020),
which may be a potential mechanism for viral dissemination.
Our studies indicate that the enhanced virus binding and inter-
nalization of MAYV facilitated by non-neutralizing mAbs in
myeloid cell lines does not result in enhanced infection in vitro
or in vivo. This result contrasts with flaviviruses for which non-
or poorly neutralizing antibodies can promote infection of
FcgR-expressing myeloid cells through ADE (Bournazos et al.,
2020b; Halstead et al., 2010; Rey et al., 2018), which is believed
to result in severe disease during secondary dengue infection
(Halstead, 1988). In comparison, ADE and pathogenic antibodies
that enhance myeloid cell infections are not believed to
contribute to alphavirus pathogenesis, although one study re-
ported higher viremia and worse arthritis in mice in the setting
of passive transfer of an anti-CHIKV mAb (Lum et al., 2018).
Clearly, studies that examine the effects of in vivo passive trans-
fer of antibodies with no, weak, or potently neutralizing activity
with multiple alphaviruses are needed to establish the generaliz-
ability of our findings.
Antibody-dependent protection against alphaviruses is facili-
tated by two main functions, as follows: Fab-mediated virus
neutralization and Fc-dependent effector functions. Data from
this study and others (Earnest et al., 2019; Fox et al., 2015; Jin
and Simmons, 2019; Pal et al., 2013) suggest that neutralization
and Fc effector functions can control alphavirus infections
through a range of mechanisms. Analyzing the polyclonal anti-
body response to infection by MAYV or other alphaviruses in
the context of natural infection or immunization (Choi et al.,
2019; Weise et al., 2014) to determine the relative amounts of
neutralizing and non-neutralizing antibodies may provide insight
as to which functions ultimately are most important for control-
ling infection.
The efficacy of a protective antibody response to alphavirus
infection is determined by the location of antibody binding on
intact virions and structural proteins displayed on the surface
of infected cells, the inherent neutralizing ability andmechanism
(blockade of attachment, entry, fusion, or egress), and likely the
accessibility of the Fc region of antibodies to engage FcgR and
mediate effector functions. Because accelerated virus clear-
ance might mitigate the development of chronic musculoskel-
etal disease, designing vaccines and analyzing antibody
responses in the context of effector function responses may
be important. Although many neutralizing anti-alphavirus
mAbs have been described that bind the A and B domain of
E2, our study shows that non-neutralizing mAbs recognizing
epitopes within or near the A domain also can prevent or clear
virus from infected hosts by optimal effector functions. The six
epitopes we identified are also highly conserved across the 73
complete MAYV genomes annotated in public databases.
Amino acid interaction residues from mAbs in groups A, D,
and F are entirely conserved, whereas there are a small number
of single amino acid substitutions in binding residues from
mAbs in group B (9/73 strains with amino acid substitution at
T55), C (2/73 strains with amino acid substitution at D74), or E
(1/73 strains with amino acid substitution at A161). Further anal-
ysis of human antibody responses to natural infections, in both
patients who have cleared virus and those with persistent




disease, may provide insight into the contribution of Fc effector
functions to protection and disease pathogenesis.
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P. (2008). FcgammaRIV is a mouse IgE receptor that resembles macrophage
FcepsilonRI in humans and promotes IgE-induced lung inflammation. J. Clin.
Invest. 118, 3738–3750.
Martins, K.A., Gregory, M.K., Valdez, S.M., Sprague, T.R., Encinales, L., Pa-
checo, N., Cure, C., Porras-Ramirez, A., Rico-Mendoza, A., Chang, A., et al.
(2019). Neutralizing Antibodies fromConvalescent Chikungunya Virus Patients
Can Cross-Neutralize Mayaro and Una Viruses. Am. J. Trop. Med. Hyg. 100,
1541–1544.
Nelson, C.A., Lee, C.A., and Fremont, D.H. (2014). Oxidative refolding from in-
clusion bodies. Methods Mol. Biol. 1140, 145–157.
Oliphant, T., Nybakken, G.E., Engle, M., Xu, Q., Nelson, C.A., Sukupolvi-
Petty, S., Marri, A., Lachmi, B.-E., Olshevsky, U., Fremont, D.H., et al.
(2006). Antibody recognition and neutralization determinants on
domains I and II of West Nile Virus envelope protein. J. Virol. 80,
12149–12159.
Pal, P., Dowd, K.A., Brien, J.D., Edeling, M.A., Gorlatov, S., Johnson, S., Lee,
I., Akahata, W., Nabel, G.J., Richter, M.K., et al. (2013). Development of a high-
ly protective combination monoclonal antibody therapy against Chikungunya
virus. PLoS Pathog. 9, e1003312.
Pinheiro, F.P., Freitas, R.B., Travassos da Rosa, J.F., Gabbay, Y.B., Mello,
W.A., and LeDuc, J.W. (1981). An outbreak of Mayaro virus disease in Belterra,
Brazil. I. Clinical and virological findings. Am. J. Trop. Med. Hyg. 30, 674–681.
Platzer, B., Stout, M., and Fiebiger, E. (2014). Antigen cross-presentation of
immune complexes. Front. Immunol. 5, 140.
Powell, L.A., Miller, A., Fox, J.M., Kose, N., Klose, T., Kim, A.S., Bombardi, R.,
Tennekoon, R.N., Dharshan de Silva, A., Carnahan, R.H., et al. (2020). Human
mAbs Broadly Protect against Arthritogenic Alphaviruses by Recognizing
Conserved Elements of the Mxra8 Receptor-Binding Site. Cell Host Microbe
28, 699–711.e7.
Renner, M., Flanagan, A., Dejnirattisai, W., Puttikhunt, C., Kasinrerk, W., Su-
pasa, P., Wongwiwat, W., Chawansuntati, K., Duangchinda, T., Cowper, A.,
et al. (2018). Characterization of a potent and highly unusual minimally
enhancing antibody directed against dengue virus. Nat. Immunol. 19, 1248–
1256.
Rey, F.A., Stiasny, K., Vaney, M.C., Dellarole, M., and Heinz, F.X. (2018). The
bright and the dark side of human antibody responses to flaviviruses: lessons
for vaccine design. EMBO Rep. 19, 206–224.
Rupp, J.C., Sokoloski, K.J., Gebhart, N.N., and Hardy, R.W. (2015). Alphavirus
RNA synthesis and non-structural protein functions. J. Gen. Virol. 96, 2483–
2500.
Sheehan, K.C., Lai, K.S., Dunn, G.P., Bruce, A.T., Diamond, M.S., Heutel,
J.D., Dungo-Arthur, C., Carrero, J.A., White, J.M., Hertzog, P.J., and
Schreiber, R.D. (2006). Blocking monoclonal antibodies specific for
mouse IFN-alpha/beta receptor subunit 1 (IFNAR-1) from mice immu-
nized by in vivo hydrodynamic transfection. J. Interferon Cytokine Res.
26, 804–819.
Smith, S.A., Silva, L.A., Fox, J.M., Flyak, A.I., Kose, N., Sapparapu, G., Kho-
mandiak, S., Ashbrook, A.W., Kahle, K.M., Fong, R.H., et al. (2015). Isolation
and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies
with Therapeutic Activity against Chikungunya Virus. Cell Host Microbe 18,
86–95.
Tao, M.H., and Morrison, S.L. (1989). Studies of aglycosylated chimeric
mouse-human IgG. Role of carbohydrate in the structure and effector func-
tions mediated by the human IgG constant region. J. Immunol. 143, 2595–
2601.
Uchime, O., Fields, W., and Kielian, M. (2013). The role of E3 in pH protection
during alphavirus assembly and exit. J. Virol. 87, 10255–10262.
Waggoner, J.J., Rojas, A., Mohamed-Hadley, A., de Guillen, Y.A., and Pinsky,
B.A. (2018). Real-time RT-PCR for Mayaro virus detection in plasma and urine.
J. Clin. Virol. 98, 1–4.
Weise, W.J., Hermance, M.E., Forrester, N., Adams, A.P., Langsjoen, R.,
Gorchakov, R., Wang, E., Alcorn, M.D.H., Tsetsarkin, K., and Weaver, S.C.
(2014). A novel live-attenuated vaccine candidate for mayaro Fever. PLoS
Negl. Trop. Dis. 8, e2969.




White, J.P., Xiong, S., Malvin, N.P., Khoury-Hanold, W., Heuckeroth, R.O.,
Stappenbeck, T.S., and Diamond, M.S. (2018). Intestinal Dysmotility Syn-
dromes following Systemic Infection by Flaviviruses. Cell 175, 1198–
1212.e12.
Winkler, E.S., Shrihari, S., Hykes, B.L., Jr., Handley, S.A., Andhey, P.S., Huang,
Y.S., Swain, A., Droit, L., Chebrolu, K.K., Mack, M., et al. (2020). The Intestinal
Microbiome Restricts Alphavirus Infection and Dissemination through a Bile
Acid-Type I IFN Signaling Axis. Cell 182, 901–918.e18.
Yap, M.L., Klose, T., Urakami, A., Hasan, S.S., Akahata, W., and Rossmann,
M.G. (2017). Structural studies of Chikungunya virus maturation. Proc. Natl.
Acad. Sci. USA 114, 13703–13707.
Zhang, R., Kim, A.S., Fox, J.M., Nair, S., Basore, K., Klimstra, W.B., Rimkunas,
R., Fong, R.H., Lin, H., Poddar, S., et al. (2018). Mxra8 is a receptor for multiple
arthritogenic alphaviruses. Nature 557, 570–574.
Zhou, Q.F., Fox, J.M., Earnest, J.T., Ng, T.-S., Kim, A.S., Fibriansah, G., Kos-
tyuchenko, V.A., Shi, J., Shu, B., Diamond, M.S., and Lok, S.M. (2020). Struc-
tural basis of Chikungunya virus inhibition by monoclonal antibodies. Proc.
Natl. Acad. Sci. USA 117, 27637–27645.






REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
MAY-1, anti-MAYV mAb This Paper N/A
MAY-8, anti-MAYV mAb This Paper N/A
MAY-8-mIgG1, anti-MAYV mAb This Paper N/A
MAY-8-hIgG1, anti-MAYV mAb This Paper N/A
MAY-8-hIgG1-N297Q, anti-MAYV mAb This Paper N/A
MAY-10, anti-MAYV mAb This Paper N/A
MAY-23, anti-MAYV mAb This Paper N/A
MAY-27, anti-MAYV mAb This Paper N/A
MAY-39, anti-MAYV mAb This Paper N/A
MAY-41, anti-MAYV mAb This Paper N/A
MAY-59, anti-MAYV mAb This Paper N/A
MAY-60, anti-MAYV mAb This Paper N/A
MAY-68, anti-MAYV mAb This Paper N/A
MAY-72, anti-MAYV mAb This Paper N/A
MAY-102, anti-MAYV mAb This Paper N/A
MAY-108, anti-MAYV mAb This Paper N/A
MAY-108-mIgG1, anti-MAYV mAb This Paper N/A




MAY-112, anti-MAYV mAb This Paper N/A
MAY-117, anti-MAYV mAb Earnest et al., 2019 N/A
MAY-117-hIgG1, anti-MAYV mAb Earnest et al., 2019 N/A
E60, anti-Zika mAb Oliphant et al., 2006 N/A
MAR1-5A3, anti-Ifnar1 mAb Leinco Cat #: BP024; RRID:AB_2491621
MC-21, anti-CCR2 mAb (Mack et al., 2001) N/A
InVivomAb anti-mouse NK1.1 Bio X Cell Cat # BE0036; RRID:AB_1107737
Goat anti-mouse IgG, human ads-HRP Southern Biotech Cat # 1030-05; RRID:AB_2619742
Goat anti-mouse IgG, human ads-BIOT Southern Biotech Cat # 1030-08; RRID:AB_2794296
Goat anti-mouse IgG, human ads-
AlexaFluor 647
Invitrogen Cat # A-21236; RRID:AB_2535805
Goat anti-human IgG, HRP Thermo Fisher Cat # 62-8420; RRID:AB_2533962
Streptavidin-HRP Vector Laboratories Cat # SA-5004; RRID:AB_2336509
BUV95 anti-CD45 BD BioSciences Cat # 564279; RRID:AB_2651134
Fixable Aqua dead cell stain Invitrogen Cat # L34965
PerCP-Cy5.5 anti-CD11b BioLegend Cat # 101207; RRID: AB_312790
FITC anti-Ly6B Abcam Cat # ab53457; clone: 7/4
PE-Cy7 anti-Ly6G BioLegend Cat # 115511;
RRID: AB_313646
Pacific Blue anti-Ly6C BioLegend Cat # 128015;
RRID: AB_1732087
AlexaFluor 700 anti-MHC class II BioLegend Cat # 107621;
RRID: AB_493726
(Continued on next page)





REAGENT or RESOURCE SOURCE IDENTIFIER
APC-Cy-7 anti-CD3 BioLegend Cat # 100329;
RRID: AB_1877171
BV605 anti-CD19 BioLegend Cat # 115539;
RRID: AB_11203538
PE-Cy7 anti-NK1.1 BioLegend Cat # 108713;
RRID: AB_389363
APC anti-CD64 BioLegend Cat # 139305;
RRID: AB_11219205
APC anti-CD32b Invitrogen Cat # 17-0321-82;
RRID: AB_2573142
APC anti-CD16.2 BioLegend Cat # 149505;
RRID: AB_2565812
Virus and bacterial strains
MAYV-CH Weise et al., 2014 N/A
MAYV-BeH407 World Reference Center for Emerging
Viruses and Arboviruses, The University
of Texas Medical Branch
N/A
Zika-Dakar-MA Gorman et al., 2018 N/A
Experimental models: cell lines
Vero E6 ATCC CRL-1586; RRID:CVCL_0574
C2C12 ATCC CRL-1772;
RRID: CVCL_0188
HEK293T ATCC CRL-3216; RRID:CVCL_0063
Expi293F Invitrogen Cat # A14527; RRID: CVCL_D615
BV2 Ma et al., 2020 N/A
BV2-b4galt7 Ma et al., 2020 N/A
LADMAC ATCC CRL-2420; RRID:CVCL_2550
Experimental models: organisms/strains
Mouse: C57BL/6J Jackson Laboratory Cat # 000664; RRID: IMSR_JAX:000664




Waggoner et al., 2018 N/A
MAYV-rtPCR-R:
50-TGCTGGAAACGCTCTCTGTA-30




Waggoner et al., 2018 N/A
Zika-rtPCR-F: 50-CCACCAATGTTCTC
TTGCAGACATATTG-30
White et al., 2018 N/A
Zika-rtPCR-R: 50-TTCGGACAGCCGT
TGTCCAACACAAG-30




White et al., 2018 N/A
Gapdh TaqMan Primer/Probe set IDT Mm.PT.39a.1
Recombinant DNA
pET21a-MAYV-TRVL4675-rE2 protein Earnest et al., 2019 N/A
pCDNA3.1-MAYV-Polyprotein
(including alanine scan
mutants in E2 residues 1-174)
This Paper N/A
(Continued on next page)






Further information and requests for resources and reagents should be directed to andwill be fulfilled by the LeadContact,Michael S.
Diamond (diamond@wusm.wustl.edu).
Materials availability
All requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact author. This includes mice,
antibodies, viruses, and proteins. All reagents will be made available on request after completion of a Materials Transfer Agreement.
Data and code availability
All data supporting the findings of this study are available within the paper and are available from the corresponding author upon
request.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines
Vero, HEK293T, and C2C12 cells were cultured in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal bovine
serum (FBS), 100 U/ml of penicillin, 100 mg/ml of streptomycin, 1X MEM non-essential amino acids, 1 mM sodium pyruvate, 2 mM
L-Glutamine and 10 mMHEPES pH 7.3. Hybridomas were cultured in Isocove’s modified Eagle medium (IMDM) supplemented with
20% FBS, 100 U/ml of penicillin, 100 mg/ml of streptomycin, and 1 mM sodium pyruvate. Expi293 cells were maintained in Expi293
medium (GIBCO). BV2-Db4galt7 cells were produced previously (Ma et al., 2020). BV2, BV2-Db4galt7, and LADMAC cells weremain-
tained in DMEM supplemented with 5% FBS, 100 U/ml of penicillin, 100 mg/ml of streptomycin, 1X MEM non-essential amino acids,
and 10 mM HEPES pH 7.3.
Viruses
MAYV (strain BeH407) was obtained from the World Reference Center for Emerging Viruses and Arboviruses (K. Plante, and S.
Weaver, University of Texas Medical Branch) and passaged in Vero cells from lyophilized stocks. Recombinant viruses were pro-
duced after linearization of a prS2 vector containing cDNA fromMAYV (strain CH) (Weise et al., 2014) that was provided by S.Weaver
(University of Texas Medical Branch). After in vitro transcription with mMESSAGE mMACHINE SP6 transcription kit (Invitrogen) and
transfection into BHK-21 cells, p0 virus stocks were harvested and passaged once (p1) in Vero cells. Virus titers were determined by
focus forming assay (Fox et al., 2015). Mouse adapted Zika-Dakar virus (Gorman et al., 2018) was propagated in Vero cells.
Mouse experiments
All animal experiments and procedures were carried out in accordance with the recommendations in the Guide for the Care and Use
of Laboratory Animals of the National Institutes of Health. The protocols were approved by the Institutional Animal Care and Use
Committee at the Washington University School of Medicine (Assurance number A3381-01). Injections were performed under anes-
thesia that was induced and maintained with ketamine hydrochloride and xylazine, and all efforts were made to minimize animal
suffering.
WT C57BL/6Jmalemice were purchased from Jackson Laboratories. Common g-chain deficient (FcRg/) C57BL/6 mice were ob-
tained commercially (Taconic), backcrossed using speed congenics to C57BL/6J mice, and bred at the Washington University School
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of Medicine Animal Facility. FcRg/ experiments were performed with both male and female mice. Unless otherwise indicated, four-
week-old mice were used in all experiments. Anti-MAYV mAbs were administered by intraperitoneal injection at specified times before
or after inoculation in the left footpad with 103 FFU of MAYV in Hank’s Balanced Salt Solution (HBSS) supplemented with 1% heat-in-
activated FBS. Foot swelling was monitored via measurements (width x height) using digital calipers. Tissues were harvested after
perfusion with 40mL of PBS and titered by qRT-PCR using RNA isolated from viral stocks as a standard curve to determine FFU equiv-
alents. For lethal challenge experiments, mice were administered via intraperitoneal injection a single 100 mg dose of anti-Ifnar1 mAb
MAR1-5A3 (Sheehan et al., 2006) (BioXCell) one day before infection. Monocyte depletion experiments were performed by adminis-
tering 25 mg of anti-CCR2 (clone MC-21) at day 1 and every other day subsequently. NK cell depletion experiments were performed
by administering 200 mg of NK1.1 (BioXCell clone PK136) at day 1, and every other day subsequently.
METHOD DETAILS
Protein expression and purification
The MAYV (strain TRVL4675) E2 ectodomain (residues 1-340) was cloned into the pET21a expression vector and expressed in BL21
(DE3) E. coli cells. Protein production was induced using 1 mM isopropyl b-d-1-thiogalactopyranoside (IPTG), where E2 partitioned
into the inclusion body fraction and was refolded using an oxidative refolding protocol (Nelson et al., 2014). Briefly, 10 mL of solubi-
lized inclusion bodywas injected at 1ml/h into a 1 l volume of arginine refolding buffer (400mML-arginine, 100mMTris [pH 8.5], 5mM
reduced glutathione, 0.5 mM oxidized glutathione, and 0.2 mMPMSF), and then allowed to stir slowly overnight at 4C. The refolded
protein was filtered, concentrated using a 30 kDa cutoff stirred cell concentrator (EMD Millipore), and purified by HiLoad 16/600
Superdex 75 size exclusion chromatography (GE Healthcare).
mAb generation
Ten week-old female C57BL/6J mice were inoculated with 103 FFU of MAYV-CH. Mice were boosted with 100 mg of recombinant
MAYV E2 protein mixed 1:1 with Freund’s Incomplete adjuvant at 14, 28, and 42 days after initial infection. Spleens were harvested
at 45 dpi and fused with P3X63 Ag.8.6.5.3 mouse myeloma cells as described previously (Pal et al., 2013). Hybridoma supernatants
were screened for antibodies that bound to recombinant MAYV E2 in an ELISA and/or toMAYV (strain BeH407)-infected cells by flow
cytometry. Neat hybridoma supernatants were screened for neutralization of MAYV-CH using a FRNT (described below). Selected
mAbs were isotyped by ELISA and purified by protein A affinity chromatography (Thermo).
ELISA
For the virion capture ELISA, a humanized mAb specific for MAYV (MAY-134) (Earnest et al., 2019) was adsorbed to Maxisorp Im-
munocapture ELISA plates (Thermo) in a sodium bicarbonate buffer pH 9.3 overnight at 4C. Wells were washed with PBS and
blocked with blocking buffer (PBS + 5% BSA [Sigma]) for 1 h at 37C. Blocking buffer was removed and replaced with 103 FFU/
well of MAYV-BeH407 diluted in blocking buffer and incubated at 37C for 1 h. Unbound virus was washed away with PBS and serial
dilutions of anti-MAYV mAbs, diluted in blocking buffer, were added to the wells and incubated for 1 h at 4C. Unbound mAb was
washed away with PBS, and wells were incubated with an HRP conjugated goat anti-mouse Fc antibody for 1 h at 4C. Plates
were washed and developed with TMB one-step substrate (Thermo) for 10 minutes. The reaction was stopped with 1 N H2SO4,
and absorbance was measured at 450 nm. For the mAb competition binding ELISA, virus was captured to plates as above and incu-
bated with 10 mg/ml of the indicated primary mAbs. UnboundmAbs were rinsed away, and wells were incubated with 10 ng/ml of the
secondary mAbs labeled with NHS-Biotin (Thermo). After washing, biotinylated mAbs were detected using a streptavidin-HRP sec-
ondary (Vector Laboratories). For the E2 protein ELISA, 50 ng/well of bacterially produced recombinant MAYV E2 ectodomain was
adsorbed to plates as above. Plateswerewashedwith ELISAwash buffer (PBS+ 0.05%Tween 20) and incubatedwith serial dilutions
of anti-MAYV mAbs diluted in blocking buffer. MAbs were detected using secondary reagents and OD was measured as described
above.
Focus reduction neutralization tests (FRNT)
Anti-MAYV mAbs were diluted serially and incubated with 102 FFU of MAYV-BeH407 for 1 h at 37C in triplicate wells. Virus-mAb
mixtures were incubated on Vero or C2C12 cells for 60min at 37Cbefore being overlaid with 1%methylcellulose inminimal essential
medium (MEM) supplemented with 10 mM HEPES pH 7.3, 100 U/ml of penicillin, 100 mg/ml of streptomycin, 2 mM L-glutamine, and
2%FBS. Eighteen hours after virus inoculation, cells were fixedwith 1%paraformaldehyde (PFA) in PBS. Cells thenwerewashed and
overlaid with 1 mg/ml of biotinylated MAY-118 (Earnest et al., 2019) for 2 h. Cells were washed and overlaid with streptavidin-HRP for
1 h. Foci of infection were detected using TrueBlue substrate (KPL) and counted using a Biospot plate reader (Cellular Technology).
Wells containing virus incubated with mAbs were compared to wells treated with virus containing no mAb.
Western blotting
Recombinant MAYV-E2 protein was mixed with LDS buffer (Life Technologies) in the presence (reducing) or absence (non-
reducing) of 20 mM dithiothreitol. After heating at 70C for 10 min, samples were electrophoresed using a 4%–12% Bis-Tris gel
(Life Technologies). Proteins were transferred to nitrocellulose membranes using an iBlot2 Dry Blotting System (Life Technologies).




Membranes were blocked with 5% BSA, cut into strips, and probed with the indicated mAbs. Unbound mAb was rinsed away, and
themAbswere detected with an anti-mouse HRP-conjugated secondary antibody (Vector Laboratories). Blots were developed using
SuperSignal West Pico Chemiluminescent Substrate (Life Technologies).
Biolayer interferometry
The binding affinity of purified recombinant MAYV E2 ectodomain protein to MAYV mAbs was evaluated at 25C using an Octet-
Red96 device (Pall ForteBio). 100 mg of each mAb was mixed with biotin (EZ-Link-NHS-PEG4-Biotin, Thermo Fisher) at a molar ratio
of 20:1 biotin:protein and incubated at room temperature for 30 min. The unreacted biotin was removed by passage through a de-
salting column (5mLZeba Spin 7 kDamolecular weight cut-off, Thermo Fisher). The biotinylated-mAbswere loaded onto streptavidin
biosensor pins (ForteBio) until saturation, typically 10 mg/ml for 2 min, in 10 mMHEPES (pH 7.4), 150 mMNaCl, 3 mM EDTA, 0.005%
P20 surfactant, and 1% BSA. The pins were equilibrated in binding buffer alone before being plunged into wells containing various
concentrations of MAYV E2, then being placed back into binding buffer to allow for dissociation. Real-time data were analyzed using
BIAevaluation 3.1 (GE Healthcare). Kinetic profiles and steady-state equilibrium concentration curves were fitted using a global 1:1
binding algorithm with drifting baseline.
Alanine scanning mutagenesis
ApcDNA3.1(+) plasmid expressing a codon-optimizedMAYV (strain TRVL4675) structural polyprotein (C, E3, E2, 6K, andE1genes)was
synthesized andmutated byGenScript. Alanine scanningmutagenesis was performed on amino acids in the A domain of the E2 protein
(residues 1-173) that were predicted to be solvent exposed. Plasmids were transfected into HEK293T cells using Lipofectamine 3000
(Thermo Fisher). Eighteen hours later, cells were chilled to 4C, washed with PBS, and incubated with anti-MAYV mAbs (10 mg/ml) in
PBSwith 2%FBS for 1 hat 4C.Anoligoclonalmixture of the 13mAbsaswell asananti-BdomainmAb (MAY-117)was usedasa control
formutantE2protein expression. Anti-MAYVmAbbindingwasdetectedusingAlexa Fluor 647conjugatedgoat anti-mouse IgG (Thermo
Fisher) diluted 1:1000. After 1 h, cells were washed, fixed with 1% PFA in PBS, and analyzed by flow cytometry using a MACSQuant
Analyzer (Miltenyi Biotec). Using previously described criteria (Smith et al., 2015), critical residues were defined as those with% 25%
binding to an individual mAb butR 75% binding to an oligoclonal pool of anti-MAYV mAbs as determined by flow cytometry.
Isotype switching of mAbs
MAY-10 andMAY-108 variable regions were sequenced and cloned using previously describedmethods (Ho et al., 2016). Total RNA
was isolated from hybridomas and cDNA was produced using random hexamers and Oligod(T)20 using a SuperScript IV First Strand
Synthesis kit (Invitrogen). Heavy and light chain variable regionswere amplified and sequenced usingmouse-specific primer sets (Ho
et al., 2016). Allele-specific primers were used to amplify variable regions and append Gibson assembly sequences to the 50 and 30
ends. The variable regions then were cloned into plasmids containing the constant regions of human IgG1 (pAbVec-hIgG1) or mouse
IgG1 (pAbVec-mIgG1) or the appropriate kappa chain (pAbVec-hIgKappa or pAbVec-mIgKappa) using NEBuilder (New England Bio-
labs). The human IgG1-N297Q vector was produced by site directed mutagenesis of the human IgG1 vector using a Phusion site
directed mutagenesis kit. Antibodies were produced by co-transfecting Expi293 cells with an appropriate heavy and kappa chain
plasmid using Hype5 transfection reagent (Oz Biosciences). Four days after transfection, supernatant was collected and mAbs
were purified on a Pierce protein A agarose column (Thermo).
Cytokine analysis
Ankle homogenates were incubated with Triton X-100 (1% final concentration) for 1 h at room temperature to inactivate MAYV. Ho-
mogenates then were analyzed for cytokines and chemokines by Eve Technologies Corporation (Calgary, AB, Canada) using their
Mouse Cytokine Array/Chemokine Array 31-Plex platform.
Flow cytometry
For cell depletion experiments, whole blood was harvested from mice and mixed with 5 mM EDTA (Corning). Red blood cells were
lysed with ACK lysis buffer at room temperature before being washed and chilled in PBS + 5% FCS. Monocytes were stained with
CD45 BUV395 (BD Biosciences clone 30-F11), CD11b PerCP-Cy5.5 (BioLegend clone M1/70), Ly6B FITC (Abcam clone 7/4), Ly6G
PE-Cy7 (BioLegend clone 6D5), Ly6C Pacific Blue (BioLegend clone HK1.4) and MHC class II A700 (BioLegend clone M5/114.15.2).
NK cells were stained with CD45 BUV95, CD3 APC-Cy-7 (BioLegend clone 145-2C11), CD19 BV605 (BioLegend clone 6D5), and
NK1.1 Pe-Cy7 (BioLegend clone PK136). Viability was determined through exclusion of a fixable viability dye (e506;eBiosciences).
Samples were fixed and processed on a BD-Fortessa X20. For FcgR expression experiments BV2, LADMAC, and Vero cells were
stained with one of the following: CD64 APC (BioLegend clone X54-5/7.1), CD32b APC (Invitrogen clone AT130-2), CD16 FITC (Bio-
Legend clone 221-3A4), CD16.2 APC (BioLegend clone 9E9). Cells were analyzed on aMACSQuant analyzer (Miltenyi). All FACS data
were analyzed by FlowJo v. 10.7.
Antibody-induced depletion of MAYV from cell supernatants
MAYV was treated with 100 mg/ml of RNase A (Thermo #EN0531) for 30 min at 37C to degrade unencapsidated RNA. RNase was
inactivated by incubating samples with 100 U of RiboLock RNase inhibitor (Thermo #E00381) at 37C for 15 minutes. 103 FFU of




RNase-treated virus was incubated with serial dilutions of the indicated mAb for 30 min at 37C. Virus-mAb complexes were placed
on cells and incubated for 30 min at 37C. The virus inoculum then was removed and viral RNA was isolated using a MagMax Viral
Isolation Kit (Applied Biosystems). MAYVRNAwas quantified using a Taqman RNA-to-Ct 1-step kit (Thermo Fisher) and a 50 UTR and
nsp1 specific primer/probe set (Waggoner et al., 2018) along with a standard curve of MAYV stock virus.
Antibody-induced virus binding/internalization assay
Target cells were counted, and the indicated mAbs were incubated for 30min at 37Cwith MAYV at amultiplicity of infection (MOI) of
10. Virus-antibody complexes were added to cells and incubated at 37C for 1 h. Cells were washed six times with ice cold PBS and
lysed in RLT buffer (QIAGEN). Viral RNAwas isolated using aMagMax Viral Isolation Kit. MAYV RNA and GAPDHRNAwas quantified
using a Taqman RNA-to-Ct 1-step kit with either anti-MAYV primers or anti-mouse Gapdh primer/probe. Data are expressed as
amount of MAYV RNA relative to GAPDH RNA. For internalization assays, the same protocol was followed, but after rinsing mono-
layers after 1 h incubation at 37C, cells were treated with 100 mg/ml of proteinase K (Invitrogen) for 15 min at 37C. Proteinase K was
rinsed away, and cells were treated with 100 mg/ml of RNase A for 30 min at 37C. Cells were lysed, and viral RNA was detected from
cellular lysates as described above.
Antibody dependent enhancement assays
For MAYV, target cells were counted and the indicated mAbs were incubated for 30 min at 37C with MAYV at a MOI of 10. Virus-
antibody complexes were added to cells and incubated at 37C for 1 h. Unabsorbed virus was removed by washing cells 6X with
37C DMEM. Cells were incubated at 37C in DMEM + 2% FBS for 7 additional hours. Cells were lysed and viral RNA was quantified
as described above.
For ZIKV, target cells were counted and either MAY-10 or the cross-reactive anti-E mAb E60 (Oliphant et al., 2006) were pre-incu-
bated with ZIKV for 30 min at 37C. Virus-antibody complexes were added to the cells at an MOI of 50 and incubated at 37C for 2 h.
Unabsorbed virus was removed by rinsing cells six timeswith DMEM.Cells were incubated at 37C inDMEM+2%FBS for 16 h. Cells
were lysed and viral RNA was quantified using a published primer/probe set (White et al., 2018).
MAYV E2-E1 structure depiction
Structural figures were created using UCSF ChimeraX (Goddard et al., 2018). The predicted structure of the MAYV E2-E1 monomer
was generated as previously described (Earnest et al., 2019). To depict the envelope proteins as a trimeric spike, the predictedmono-
mers were superimposed onto themodel of the CHIKV E2-E1 spike (PDB: 6NK5) using thematchmaker command in UCSFChimeraX
(Goddard et al., 2018).
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical significance was assigned with P values < 0.05 using GraphPad Prism version 7.0. The specific test for each dataset is indi-
cated in respective figure legends and was selected based on the number of comparison groups and variance of the data. For foot
swelling analysis, significance was determined by a two-way ANOVA with Tukey’s post-test (more than two groups) or Sidak’s post-
test (between two groups). Viral burden data were analyzed by a one-way ANOVA with a Dunnett’s post-test. Survival curve analysis
was analyzed by the log rank test. A Bonferroni correction was used depending on the number of comparison groups.
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Figure S1. ELISA and BLI analysis of mAb binding to MAYV E2, related to Table 1. (A) Maximal ELISA OD 
values for anti-MAYV mAbs binding to MAYV (strain BeH407) captured by a human antibody specific to MAYV. 
10 µg/ml of the indicated mAb was added to the captured MAYV. After unbound mAb was rinsed away, bound 
mAb was detected with an anti-mouse HRP secondary antibody. Data are the average of two experiments performed 
in triplicate. (B) Western blot analysis with indicated anti-MAYV mAb binding to recombinant E2 protein under 
non-reducing and reducing conditions. MAY-117 is an example of a mAb (neutralizing, B domain) that binds a 
conformationally-sensitive epitope. Anti-WNV mAb E60 is a negative isotype control mAb. (C) BLI analysis of 
anti-MAYV mAb binding to recombinant E2 protein. Biotinylated mAbs were bound to streptavidin pins and 
plunged into wells containing 500, 100, 20, 4 or 0 µg/ml recombinant E2 proteins. Binding of E2 to the mAbs was 







Figure S2. Epitope mapping of anti-MAYV mAbs, related to Fig 2 and Table S1. (A-F) 293T cells were 
transfected with a C-E3-E2-6K-E1 plasmid containing alanine mutations in the A domain of E2. Binding of the 
indicated mAbs were measured by flow cytometry; the full data set is shown in Table S1. Critical residues were 
defined as those with <25% binding (dotted line) to an individual mAb but >75% binding to an oligoclonal pool of 
anti-MAYV mAbs. Data are from two experiments. (a, P < 0.05; b, P < 0.01; c, P < 0.001; d, P < 0.0001 compared 







Figure S3. Competition binding between MAY-134 and MAY-10 and MAY-108, related to Fig 3. The anti-
MAYV E2 B domain mAb MAY-134 was competed with MAY-10 or MAY-108 for binding to MAYV strain 
BeH407 by ELISA. Virus was captured using a human anti-MAYV mAb and incubated with 10 µg/ml of the 
indicated mAb (First Antibody). Unbound mAb was rinsed away, and antibody-virus complexes were incubated 
with 10 ng/ml of the indicated mAb labeled with biotin (Second Antibody). After a short incubation, unbound 
biotinylated mAb was rinsed away, and binding was detected using streptavidin HRP. Data are the average of two 






Figure S4. Cytokine levels in ipsilateral ankle of infected mice treated with MAY-10-hIgG1 or MAY-10-
hIgG1-N297Q, related to Fig 5. Four-week-old C57BL/6J mice were treated with 100 µg of MAY-10-hIgG1, 
MAY-10-hIgG1-N297Q, or an isotype control mAb one day before subcutaneous infection with 103 FFU MAYV. 
At 7 dpi, mice were sacrificed and ipsilateral ankles were harvested. These tissues were homogenized and analyzed 
for expression of the indicated cytokines. Data are pooled from three experiments (n = 11, one-way ANOVA with 







Figure S5. Flow cytometry analysis of monocyte and NK cell depletion, related to Fig 6. Four-week old female 
anti-Ifnar1 mAb-treated C57BL/6 mice were administered an isotype control mAb, 25 µg/mouse of ant-CCR2 (A), 
or 200 µg of anti-NK1.1 (B) one day before infection with 103 FFU of MAYV. Mice again were treated with the 
indicated antibody at 1, 3, and 5 dpi. At 7 dpi, whole blood was collected and analyzed by flow cytometry. 
Monocytes were defined as CD45+, Ly6b+ CD11b+ double-positive, Ly6G-, and Ly6Chi cells. NK cells were defined 






Figure S6. FcgR expression on BV2 and LADMAC cells, related to Fig 6. FcgR expression in BV2, BV2-
b4galt7, and LADMAC cell lines. The indicated cells were incubated with fluorescently-labeled mAbs specific for 








Figure S7. Antibody mediated binding and enhancement assays, related to Fig 6. A-H. Antibody-mediated 
binding of MAYV to BV2-b4galt7 (A, B, E, and F) or LADMAC (C, D, G, and H) cells. Virus binding to cells 
was measured indirectly via the depletion of MAYV from supernatants (A-D) or by direct binding and 
internalization of target cells (E-H). For measuring supernatants, 103 FFU of MAYV was incubated with the 
indicated amount of IgG2c versions of MAY-10 (A and C) or MAY-108 (B and D) for 1 h at 37oC before adding to 
the indicated cell for 30 min at 37oC when supernatants were collected. Viral RNA from supernatants was measured 
by qRT-PCR. To measure virus binding and internalization, BV2-b4galt7 or LADMAC cells were inoculated with 
MAYV that had been pre-incubated with IgG2c versions of MAY-10 (E and G) or MAY-108 (F and H). After 30 
min at 37oC, cells were washed with PBS, lysed, and viral RNA was measured using qRT-PCR. I-L. Antibody-
dependent infection assays. Serial dilutions of mAbs were pre-incubated with MAYV before adding to permissive 
BV2 cells (I and J) or non-permissive BV2-b4galt7 cells (K and L). Binding and internalization into cells was 
measured as above (E-H) at 1 or 8 hpi after removal of unbound virus. Data are the mean and SD of three 
independent experiments performed in triplicate (one-way ANOVA with Dunnett’s post-test compared to the 
isotype mAb control). M-O ADE of ZIKV infection in BV2 (M), BV2-b4galt7 (N), and LADMAC (O) cell lines. 
ZIKV was incubated with the indicated concentration of MAY-10 or the anti-flavivirus mAb E60 for 30 min at 
37oC. Antibody-virus complexes were incubated on the indicated cells for 2 h at 37oC at an MOI of 50. Unabsorbed 
virus was rinsed away, and cells were incubated for 16 h at 37oC. Cells were lysed and viral RNA levels were 
determined by qRT-PCR. Data are displayed relative to a GAPDH control. The dashed line represents the limit of 






Figure S8. Proteinase K treatment of cell-associated virions, related to Fig 6. The indicated cell lines were 
incubated with antibody-virus complexes as described in Figure 6 and S4. After rinsing way unbound virus, the 
cells were incubated with 100 µg/ml of proteinase K to remove any virions not internalized in the cells. Proteinase K 
was rinsed away, unencapsidated viral RNA was removed with RNAse A treatment, and cells were lysed. 
Internalized viral RNA was detected as described in Figures 6 and S4. Data are the mean and SD of three 
independent experiments performed in triplicate (two-way ANOVA with Sidak’s post-test). In this Figure: *, P < 
0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. 
